Abstract

Progressive supranuclear palsy (PSP) is a 4R-tauopathy predominated by subcortical pathology in neurons, astrocytes, and oligodendroglia associated with various clinical phenotypes. In the present international study, we addressed the question of whether or not sequential distribution patterns can be recognized for PSP pathology. We evaluated heat maps and distribution patterns of neuronal, astroglial, and oligodendroglial tau pathologies and their combinations in different clinical subtypes of PSP in postmortem brains. We used conditional probability and logistic regression to model the sequential distribution of tau pathologies across different brain regions. Tau pathology uniformly predominates in the neurons of the pallido-nigro-luysian axis in different clinical subtypes. However, clinical subtypes are distinguished not only by total tau load but rather cell-type (neuronal versus glial) specific vulnerability patterns of brain regions suggesting distinct dynamics or circuit-specific segregation of propagation of tau pathologies. For Richardson syndrome (n = 81) we recognize six sequential steps of involvement of brain regions by the combination of cellular tau pathologies. This is translated to six stages for the practical neuropathological diagnosis by the evaluation of the subthalamic nucleus, globus pallidus, striatum, cerebellum with dentate nucleus, and frontal and occipital cortices. This system can be applied to further clinical subtypes by emphasizing whether they show caudal (cerebellum/dentate nucleus) or rostral (cortical) predominant, or both types of pattern. Defining cell-specific stages of tau pathology helps to identify preclinical or early-stage cases for the better understanding of early pathogenic events, has implications for understanding the clinical subtype-specific dynamics of disease-propagation, and informs tau-neuroimaging on distribution patterns.

Highlights

  • Progressive supranuclear palsy (PSP) is a four-repeat (4R) tauopathy that belongs to the group of frontotemporal lobar degeneration (FTLD-tau) disorders [34]

  • FDG-Positron Emission Tomography (PET) studies on PSP do not show significant hypometabolism in the occipital lobe [46], it must be noted that we observe only relatively mild tau pathology. In this neuropathology staging system we focus on astroglial tau pathology, which might not associate with significant hypometabolism detectable by FDG-PET

  • Our study supports the notion that the initiating site of neuronal degeneration and tau pathology seems to be similar in clinical subtypes, but the dynamics and propagation patterns distinguish them

Read more

Summary

Introduction

Progressive supranuclear palsy (PSP) is a four-repeat (4R) tauopathy that belongs to the group of frontotemporal lobar degeneration (FTLD-tau) disorders [34]. Following the proposal of typical, atypical, and combined cases of PSP by Lantos [26], Williams et al provided evidence for biochemical and tau pathology load differences. Acta Neuropathologica (2020) 140:99–119 between PSP with Parkinsonism (PSP-P) and the classical clinical phenotype Richardson syndrome (PSP-RS) [47, 48]. Further clinical phenotypes with PSP-type tau pathology were described [6]. In 2017, the Movement Disorders Society suggested clinical diagnostic criteria to recognize these distinct clinical subtypes as PSP-RS, PSPP, PSP with corticobasal syndrome (PSP-CBS), PSP with progressive gait freezing (PSP-PGF), PSP with predominant ocular motor dysfunction (PSP-OM), with predominant postural instability (PSP-PI), with predominant frontal presentation (PSP-F), or with predominant speech and language disorder (PSP-SL) [14]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call